

ASX Release

Appendix 4C – Q1 2026 Quarterly Cash Flow Report

27 April 2026 – Melbourne, Australia – Oneview Healthcare PLC (ASX:ONE) (“Oneview” or “the Company”), a global healthcare technology company, today released its Appendix 4C – Quarterly Cashflow report for the quarter ending 31 March 2026 (Q1 26) and provided an update on business activities.

Financial Highlights

Oneview’s cash balance at 31 March 2026 was €10.3 million (A\$17.1m) compared to €4.6 million (A\$8.1m) at 31 December 2025.

During the quarter, the Company completed a two-tranche placement of CHES Depositary Interests over fully paid ordinary shares (New CDIs) to institutional and sophisticated investors, raising approximately A\$19 million (approximately €11.4 million) in gross proceeds. Tranche 1 of the Placement, which raised A\$12 million (approximately €7.2 million), was settled on 24 March 2026. The Company’s cash balance at 31 March 2026 includes approximately €6.8 million of net proceeds from Tranche 1, after deducting approximately €0.4 million of fundraising transaction costs incurred to date.

Tranche 2 of the Placement, which is expected to raise a further A\$7 million (approximately €4.2 million) in gross proceeds, is subject to shareholder approval. Settlement of Tranche 2 will occur following receipt of this approval, which the Company expects to seek at its annual general meeting anticipated to be held in September 2026, rather than incur the unnecessary costs and distraction of calling an EGM solely for this purpose.

Subsequent to quarter end, the Company completed its Security Purchase Plan (SPP), which had been conducted in conjunction with the previously announced two-tranche institutional placement. The SPP closed on 10 April 2026 and was completed on 17 April 2026, raising approximately A\$0.3 million in gross proceeds, with all valid applications accepted in full. The proceeds from the SPP were received after 31 March 2026 and are therefore not included in the Company’s cash balance at quarter end.

Excluding the net proceeds received from the Placement, the Company had a net cash outflow of €1.1m during the quarter compared to an outflow of €1.6m in the same quarter of the prior year. The lower outflow is primarily due to lower net operating costs in the first quarter of 2026 compared to the same period of 2025 due to the business restructuring completed in June 2025. This is partially offset by lower customer receipts of €3.3 million in the first quarter of 2026 compared to €4.2 million during the same period of 2025 which included two large

customer receipts totalling over €2 million, which were due to be received during the fourth quarter of 2024 but were received during the first weeks of January 2025.

In accordance with ASX Listing Rule 4.7C, payments made to related parties and their associates are included in item 6.1 of the Appendix 4C. Payments to related parties of the entity and their associates in the quarter were comprised of directors' fees and salaries totalling €434,475 (A\$741,418).

Operational Activities

Sales and Customer Updates

The Company remains focused on continuing to expand its customer base during 2026 by advancing opportunities across its Baxter and direct sales pipelines. Progress achieved during the first quarter provides a solid foundation to support continued momentum as the year progresses. As previously announced, in January 2026 Baxter finalised an amendment to Baxter's National Care Communication Agreement with the group purchasing organisation of one of the United States ten largest health systems to include Oneview's products. This health system has over 85 hospitals and over 15,000 beds and is now in direct negotiations with Oneview over the scope and timing of the initial project for this health system.

The Company concluded its traditionally strongest quarter for lead generation, supported by participation in several major industry conferences, including ViVE Health in Los Angeles, HIMSS in Las Vegas and the AONL Conference in Chicago.

Engagement at these events continued to highlight the relevance of bedside technology as healthcare providers continue to invest in the virtualisation of care as a way to combat continued workforce challenges.

In addition to new customer opportunities, the Company is actively progressing a number of expansion project opportunities with existing customers. These projects include the extension of deployments across additional locations and new facilities, as well as customers adopting additional in-room modalities such as digital door signs and digital whiteboards. This expansion activity reflects the scalability of the Company's platform and supports incremental growth through increased utilisation within established customer relationships.

Product Updates

During the quarter, the Company continued to progress the development of Ovie, its AI-enabled digitally integrated Care Assistant, which supports the orchestration of care within the patient room. Building on the voice assistant introduced in 2025, Ovie is being developed as an orchestration layer to streamline non-clinical workflows by enabling patient self-service, more efficient request routing and improved operational visibility for care teams. Development activity also advanced on the redesigned patient user interface, which will underpin the Ovie ecosystem and is expected to be commercially available during the second half of 2026. The Company plans to commence pilot deployments of Ovie with selected customers during 2026, supporting validation of workflows and scalability ahead of general availability.

Outlook

CEO James Fitter commented, "The first quarter of the year has been a busy period for the business, with continued engagement across our sales channels and progress that supports our objectives for 2026. Momentum in the quarter reflects the ongoing virtualisation of care across health systems, which continues to be a key driver of adoption as providers seek more digitally enabled, efficient models of care. This momentum is evident not only in new customer opportunities, but also through expansion projects with existing customers as deployments extend to additional facilities and in-room modalities.

The successful completion of the recent capital raise in extremely challenging market conditions represents a strong endorsement of Oneview's strategy and execution. I would like to thank our existing shareholders for their continued support and warmly welcome new shareholders who have joined the register through the Placement.

With a strengthened balance sheet, continued deployment activity across new and existing customers, and growing demand for digitally supported bedside experiences, the Company is well positioned to maintain momentum as we progress through the year."

This announcement has been approved for release by the board of Oneview Healthcare plc.

About Oneview Healthcare plc

For healthcare systems who lead on exemplary care, Oneview Healthcare plc provides digital tools for patients, families and caregivers to improve the care experience. Unifying a facility's systems, content and services into one digital platform with dedicated devices at the point of care, Oneview helps deliver more control for patients and families, more time for care teams, and less complexity for executives and IT teams. Oneview is proud to partner with leading healthcare systems in the US, Australia, Ireland, the Middle East and Asia to unify the care experience, in over 80 hospitals.

Enquiries:

James Fitter, CEO

Darragh Lyons, CFO

Website : www.oneviewhealthcare.com

Appendix 4C

Quarterly cash flow report for entities subject to Listing Rule 4.7B

Name of entity

Oneview Healthcare PLC

ABN

610 611 768

Quarter ended ("current quarter")

 31st March 2026

Consolidated statement of cash flows	Current quarter €'000	Year to date (3 months) €'000
1. Cash flows from operating activities		
1.1 Receipts from customers	3,263	3,263
1.2 Payments for		
(a) research and development	595	595
(b) product manufacturing and operating costs	(582)	(582)
(c) advertising and marketing	(195)	(195)
(d) leased assets	-	-
(e) staff costs	(2,849)	(2,849)
(f) administration and corporate costs	(1,041)	(1,041)
1.3 Dividends received (see note 3)	-	-
1.4 Interest received	6	6
1.5 Interest and other costs of finance paid	-	-
1.6 Income taxes (paid)/refunded	-	-
1.7 Government grants and tax incentives	-	-
1.8 Other (working capital movements)	(466)	(466)
1.9 Net cash from / (used in) operating activities	(1,269)	(1,269)

2.	Cash flows from investing activities		
2.1	Payments to acquire or for:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	(100)	(100)
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.2	Proceeds from disposal of:		
	(a) entities	-	-
	(b) businesses	-	-
	(c) property, plant and equipment	-	-
	(d) investments	-	-
	(e) intellectual property	-	-
	(f) other non-current assets	-	-
2.3	Cash flows from loans to other entities	-	-
2.4	Dividends received (see note 3)	-	-
2.5	Other (provide details if material)	-	-
2.6	Net cash from / (used in) investing activities	(100)	(100)

3.	Cash flows from financing activities		
3.1	Proceeds from issues of equity securities (excluding convertible debt securities)	7,224	7,224
3.2	Proceeds from issue of convertible debt securities	-	-
3.3	Proceeds from exercise of options	-	-
3.4	Transaction costs related to issues of equity securities or convertible debt securities	(409)	(409)
3.5	Proceeds from borrowings	-	-
3.6	Repayment of borrowings	-	-
3.7	Transaction costs related to loans and borrowings	-	-
3.8	Dividends paid	-	-
3.9	Other (provide details if material)	-	-
3.10	Net cash from / (used in) financing activities	6,815	6,815

4.	Net increase / (decrease) in cash and cash equivalents for the period		
4.1	Cash and cash equivalents at beginning of period	4,602	4,602
4.2	Net cash from / (used in) operating activities (item 1.11 above)	(1,269)	(1,269)
4.3	Net cash from / (used in) investing activities (item 2.6 above)	(100)	(100)
4.4	Net cash from / (used in) financing activities (item 3.10 above)	6,815	6,815
4.5	Effect of movement in exchange rates on cash held	266	266
4.6	Cash and cash equivalents at end of period	10,315	10,315

5.	Reconciliation of cash and cash equivalents at the end of the quarter (as shown in the consolidated statement of cash flows) to the related items in the accounts	Current quarter €'000	Previous quarter €'000
5.1	Bank balances	10,315	4,602
5.2	Call deposits	-	-
5.3	Bank overdrafts	-	-
5.4	Other (provide details)	-	-
5.5	Cash and cash equivalents at end of quarter (should equal item 4.6 above)	10,315	4,602

6.	Payments to related parties of the entity and their associates	Current quarter €'000
6.1	Aggregate amount of payments to related parties and their associates included in item 1	434
6.2	Aggregate amount of payments to related parties and their associates included in item 2	-

Note: if any amounts are shown in items 6.1 or 6.2, your quarterly activity report must include a description of, and an explanation for, such payments.

7. Financing facilities	Total facility amount at quarter end €'000	Amount drawn at quarter end €'000
<i>Note: the term "facility" includes all forms of financing arrangements available to the entity. Add notes as necessary for an understanding of the sources of finance available to the entity.</i>		
7.1 Loan facilities	-	-
7.2 Credit standby arrangements	-	-
7.3 Other (please specify)	-	-
7.4 Total financing facilities	-	-
7.5 Unused financing facilities available at quarter end		-
7.6 Include in the box below a description of each facility above, including the lender, interest rate, maturity date and whether it is secured or unsecured. If any additional financing facilities have been entered into or are proposed to be entered into after quarter end, include a note providing details of those facilities as well.		

8. Estimated cash available for future operating activities	€'000
8.1 Net cash from / (used in) operating activities (item 1.9)	(1,269)
8.2 Cash and cash equivalents at quarter end (item 4.6)	10,315
8.3 Unused finance facilities available at quarter end (item 7.5)	-
8.4 Total available funding (item 8.2 + item 8.3)	10,315
8.5 Estimated quarters of funding available (item 8.4 divided by item 8.1)	8.1
<i>Note: if the entity has reported positive net operating cash flows in item 1.9, answer item 8.5 as "N/A". Otherwise, a figure for the estimated quarters of funding available must be included in item 8.5.</i>	
8.6 If item 8.5 is less than 2 quarters, please provide answers to the following questions:	
8.6.1 Does the entity expect that it will continue to have the current level of net operating cash flows for the time being and, if not, why not?	
Answer: N/a	
8.6.2 Has the entity taken any steps, or does it propose to take any steps, to raise further cash to fund its operations and, if so, what are those steps and how likely does it believe that they will be successful?	
Answer: N/a	
8.6.3 Does the entity expect to be able to continue its operations and to meet its business objectives and, if so, on what basis?	
Answer: N/a	
<i>Note: where item 8.5 is less than 2 quarters, all of questions 8.6.1, 8.6.2 and 8.6.3 above must be answered.</i>	

Compliance statement

- 1 This statement has been prepared in accordance with accounting standards and policies which comply with Listing Rule 19.11A.
- 2 This statement gives a true and fair view of the matters disclosed.

Date:24 April 2026.....

Authorised by: **BY THE BOARD**.....
(Name of body or officer authorising release – see note 4)

Notes

1. This quarterly cash flow report and the accompanying activity report provide a basis for informing the market about the entity's activities for the past quarter, how they have been financed and the effect this has had on its cash position. An entity that wishes to disclose additional information over and above the minimum required under the Listing Rules is encouraged to do so.
2. If this quarterly cash flow report has been prepared in accordance with Australian Accounting Standards, the definitions in, and provisions of, *AASB 107: Statement of Cash Flows* apply to this report. If this quarterly cash flow report has been prepared in accordance with other accounting standards agreed by ASX pursuant to Listing Rule 19.11A, the corresponding equivalent standard applies to this report.
3. Dividends received may be classified either as cash flows from operating activities or cash flows from investing activities, depending on the accounting policy of the entity.
4. If this report has been authorised for release to the market by your board of directors, you can insert here: "By the board". If it has been authorised for release to the market by a committee of your board of directors, you can insert here: "By the [name of board committee – eg *Audit and Risk Committee*]". If it has been authorised for release to the market by a disclosure committee, you can insert here: "By the Disclosure Committee".
5. If this report has been authorised for release to the market by your board of directors and you wish to hold yourself out as complying with recommendation 4.2 of the ASX Corporate Governance Council's *Corporate Governance Principles and Recommendations*, the board should have received a declaration from its CEO and CFO that, in their opinion, the financial records of the entity have been properly maintained, that this report complies with the appropriate accounting standards and gives a true and fair view of the cash flows of the entity, and that their opinion has been formed on the basis of a sound system of risk management and internal control which is operating effectively.